NLS Pharmaceutics Files Interim Financials
Ticker: NCEL · Form: 6-K · Filed: Oct 6, 2025 · CIK: 1783036
| Field | Detail |
|---|---|
| Company | Nls Pharmaceutics LTD. (NCEL) |
| Form Type | 6-K |
| Filed Date | Oct 6, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: financials, interim-report, sec-filing
TL;DR
NLS Pharmaceutics dropped its Q2 2025 financials, check the balance sheet.
AI Summary
NLS Pharmaceutics Ltd. filed an Unaudited Interim Condensed Financial Statement on October 6, 2025, for the period ending June 30, 2025. This report includes financial data for June 30, 2025, December 31, 2024, and the six-month periods ending June 30, 2025, and 2024. The company is incorporated in Switzerland and its principal executive offices are located in Zurich.
Why It Matters
This filing provides investors with an update on NLS Pharmaceutics' financial performance and position as of mid-2025, crucial for assessing the company's ongoing operations and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not contain new material events or significant changes.
Key Numbers
- 6-K — Filing Type (Report of Foreign Private Issuer)
Key Players & Entities
- NLS Pharmaceutics Ltd. (company) — Registrant
- June 30, 2025 (date) — Reporting period end date
- December 31, 2024 (date) — Comparative balance sheet date
- Zurich, Switzerland (location) — Principal executive offices
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose is to report NLS Pharmaceutics Ltd.'s Unaudited Interim Condensed Financial Statements as of June 30, 2025, and for the six months ended June 30, 2025.
What financial periods are covered by the included statements?
The statements cover June 30, 2025, December 31, 2024, and the six-month periods ended June 30, 2025, and 2024.
Where are NLS Pharmaceutics Ltd.'s principal executive offices located?
The principal executive offices are located at The Circle 6, 8058 Zurich, Switzerland.
Does NLS Pharmaceutics Ltd. file annual reports under Form 20-F or Form 40-F?
NLS Pharmaceutics Ltd. files annual reports under Form 20-F, as indicated by the checkmark next to it.
What is the SEC file number for NLS Pharmaceutics Ltd.?
The SEC file number for NLS Pharmaceutics Ltd. is 001-39957.
Filing Stats: 322 words · 1 min read · ~1 pages · Grade level 11 · Accepted 2025-10-03 21:16:29
Filing Documents
- ea0259852-6k_nlspharm.htm (6-K) — 16KB
- ea025985201ex99-1_nlspharm.htm (EX-99.1) — 442KB
- ea025985201ex99-2_nlspharm.htm (EX-99.2) — 94KB
- 0001213900-25-096255.txt ( ) — 3981KB
- nlsp-20250630.xsd (EX-101.SCH) — 43KB
- nlsp-20250630_cal.xml (EX-101.CAL) — 29KB
- nlsp-20250630_def.xml (EX-101.DEF) — 211KB
- nlsp-20250630_lab.xml (EX-101.LAB) — 404KB
- nlsp-20250630_pre.xml (EX-101.PRE) — 229KB
- ea0259852-6k_nlspharm_htm.xml (XML) — 378KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NLS Pharmaceutics Ltd. Date: October 3, 2025 By: /s/ Alexander Zwyer Name: Alexander Zwyer Title: Chief Executive Officer 3